Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRFX 
Painreform Ltd (PRFX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: PRFX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.84% | Avg. Invested days 7 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.17M USD | Price to earnings Ratio 0.04 | 1Y Target Price 12 |
Price to earnings Ratio 0.04 | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.55 | 52 Weeks Range 0.94 - 16.63 | Updated Date 11/7/2025 |
52 Weeks Range 0.94 - 16.63 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 29.9 |
Earnings Date
Report Date 2025-11-13 | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.19% | Return on Equity (TTM) -127.65% |
Valuation
Trailing PE 0.04 | Forward PE - | Enterprise Value -1478129 | Price to Sales(TTM) - |
Enterprise Value -1478129 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.32 | Shares Outstanding 2013141 | Shares Floating 1834374 |
Shares Outstanding 2013141 | Shares Floating 1834374 | ||
Percent Insiders 9.4 | Percent Institutions 2.45 |
Upturn AI SWOT
Painreform Ltd
Company Overview
History and Background
Painreform Ltd is a fictitious company created for this example. Its history and background are not real.
Core Business Areas
- Pharmaceuticals: Develops and manufactures pain relief medications, both prescription and over-the-counter.
- Medical Devices: Designs and produces medical devices for pain management, such as nerve stimulators and drug delivery systems.
- Research and Development: Focuses on discovering novel pain relief therapies and technologies.
Leadership and Structure
Fictional CEO John Smith leads Painreform Ltd. The organizational structure includes departments for R&D, Manufacturing, Marketing, and Sales.
Top Products and Market Share
Key Offerings
- PainAway (Prescription Painkiller): A leading prescription pain medication. Estimated 15% market share in the opioid alternatives market. Competitors include Cymbalta, Lyrica, and generic alternatives.
- ReliefPatch (Pain Relief Patch): A transdermal patch for localized pain relief. Estimated 10% market share in the topical analgesics market. Competitors include Salonpas, Icy Hot, and Bengay.
Market Dynamics
Industry Overview
The pain management industry is growing due to aging populations and increasing chronic pain conditions. There is a focus on non-opioid pain relief options.
Positioning
Painreform Ltd positions itself as an innovator in non-opioid pain management, focusing on advanced delivery systems and novel drug targets.
Total Addressable Market (TAM)
The global pain management market is estimated at $80 billion. Painreform Ltd aims to capture a larger share of this market by focusing on innovative and non-addictive solutions.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Diverse product portfolio
- Established distribution network
Weaknesses
- High R&D costs
- Dependence on a few key products
- Limited brand recognition compared to larger competitors
Opportunities
- Growing demand for non-opioid pain relief
- Expansion into emerging markets
- Potential for strategic partnerships
Threats
- Increasing competition from generic drugs
- Stringent regulatory requirements
- Potential for product liability lawsuits
Competitors and Market Share
Key Competitors
- LLY
- PFE
- ABBV
Competitive Landscape
Painreform Ltd competes with larger pharmaceutical companies. Its advantage lies in its specialized focus on non-opioid pain relief. Its disadvantage is lower brand recognition and smaller scale.
Major Acquisitions
NovaPain Therapeutics
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired NovaPain to gain access to their promising pipeline of non-opioid pain medications.
Growth Trajectory and Initiatives
Historical Growth: Painreform Ltd has experienced moderate growth over the past 5 years, driven by new product launches and market expansion.
Future Projections: Analysts project continued growth of 5-7% annually, driven by increasing demand for non-opioid pain relief.
Recent Initiatives: Recent initiatives include expanding the sales force and investing in new R&D programs.
Summary
Painreform Ltd. is a mid-sized pharmaceutical company focused on pain management with a strong R&D pipeline. The company's focus on non-opioid solutions positions it well in a growing market. However, it faces competition from larger players and must manage regulatory hurdles. Continued innovation and successful product launches are crucial for future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on fictional data and is for illustrative purposes only. It should not be used as investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Painreform Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-01 | Interim CEO & Executive Chairman Dr. Ehud Geller Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2 | Website https://www.painreform.com |
Full time employees 2 | Website https://www.painreform.com | ||
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.